Isoform-specific vs. pan-histone deacetylase inhibition as approaches for countering glioblastoma: an in vitro study

Our results show that the specific HDAC-6 inhibitor Tubacin had a more potent anti-proliferative effect in both the cytotoxicity and live-dead assays. The non-specific inhibitor Vorinostat surprisingly promoted migration in the cells at its 2D IC50 value treatment, and none of the inhibitors was able to significantly decrease late resistance compared to untreated controls, indicating the need for the development of more potent HDAC inhibitors for monotherapy for GBM.